Cancer Letters
Volume 225, Issue 1 , Pages 85-92 , 8 July 2005

Interferon (IFN)-β induces apoptotic cell death in DHL-4 diffuse large B cell lymphoma cells through tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Received 22 November 2004 ,Revised 30 November 2004 ,Accepted 30 November 2004.

References 

  1. Jonach E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist. 2001;6:34–55
  2. Matsui W, Huff CA, Valla M, Barber J, Smith BD, Jones RJ. Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation. Br. J. Haematol. 2003;121:251–258
  3. Mclaughin P. Progress and promise in the treatment of indolent lymphomas. Oncologist. 2002;7:217–225
  4. Panaretakis T, Pokrovskaja K, Shoshan MC, Grander D. Interferon-α-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene. 2003;22:4453–4556
  5. Dai C, Krantz SB. Interferon γ induced upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood. 1999;93:3309–3316
  6. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, et al. Mechanism of interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21:1251–1262
  7. Selleri C, Sato T, Vecchio LD, Luciano L, Barrett AJ, Rotoli B, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukaemia. Blood. 1997;89:957–964
  8. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-β compared with IFN-α2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin. Cancer Res. 2001;7:1821–1831
  9. Kito M, Akao Y, Ohishi N, Yagi K. Induction of apoptosis in cultured colon cancer cells by transfection with human interferon β gene. Biochem. Biophys. Res. Commun. 1999;257:771–776
  10. Niitsu N, Higashihara M, Honma Y. Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-γ. Leukemia Res. 2002;26:745–755
  11. Spets H, Hemming PG, Siljason J, Nilsson K, Jernberg-Wiklund H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-γ and interferon-α in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood. 1998;8:2914–2923
  12. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Kikuchi H, Sasaki S, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516–523
  13. Oshima K, Yanase N, Ibukiyama C, Yamashina A, Kayagaki N, Yagita H, et al. Involvement of TRAIL/TRAIL-R interaction in IFN-α-induced apoptosis of Daudi B lymphoma cells. Cytokine. 2001;14:193–201
  14. Ucur E, Mattern J, Wenger T, Okouoyo S, Schroth A, Debatin KM, et al. Induction of apoptosis in experimental human B cell lymphomas by conditional TRAIL-expressing T cells. Br. J. Cancer. 2003;89:2155–2162
  15. Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 1999;162:2639–2647
  16. Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001;61:1645–1651
  17. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 1999;189:1451–1460
  18. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 2000;256:56–66
  19. Gisslinger H, Kurzrock R, Gisslinger B, Jiang S, Li S, Virgolini I, et al. Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon α: involvement of tumor necrosis factor as ligand for the CD95 receptor. Blood. 2001;97:2791–2797
  20. Shin EC, Ahn JM, Kim CH, Choi Y, Ahn YS, Kim H, et al. IFN-γ induced cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int. J. Cancer. 2001;93:262–268
  21. Fonn KA, Fisher RI. Lymphomas,. In:  Beutler E,  Lichtman MA,  Coller BS,  Kipps TJ,  Seligsohn U editor. Williams Hematology;. sixth ed.. New York, NY: Mc Graw Hill; 2001;p. 1249–1251
  22. Heath RM, Jayne DG, O'Leary R, Morrison EE, Guillou PJ. Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas ligand/Fas interaction. Br. J. Cancer. 2004;90:1437–1442
  23. Damdinsuren B, Nagano H, Sakon M, Kondo M, Yamamoto T, Umeshita K, et al. Interferon-β is more potent than interferon-α in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann. Surg. Oncol. 2003;10:1184–1190
  24. Platanias LC, Uddin S, Domanski P, Colamonici OR. Differences in interferon α and β signalling. J. Biol. Chem. 1996;271:23630–23633
  25. Russell-Harde D, Wagner TC, Perez HD, Croze E. Formation of a uniquely stable type I interferon receptor complex by interferon β is dependent upon particular interactions between interferon β and its receptor and independent of tyrosine phosphorylation. Biochem. Biophys. Res. Commun. 1999;255:539–544
  26. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, et al. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signalling pathway by interferon β in human cancer cells. Cancer Res. 2003;63:5299–5307
  27. Juang SH, Wei SJ, Hung YM, Yang DM, Liu KJ, Chen WS, et al. IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines. J. Interferon Cytokine Res. 2004;24:231–243
  28. Durelli L. Is multiple sclerosis a disease that requires frequent beta interferon dosing?. J. Neurol. 2004;251(Suppl. 4):IV/13–IV/24

PII: S0304-3835(04)00962-0

doi: 10.1016/j.canlet.2004.11.054

Cancer Letters
Volume 225, Issue 1 , Pages 85-92 , 8 July 2005

Article Tools

* Image Usage & Resolution